EORTC-1333-GUCG/PEACE III trial has reached it’s primary endpoint

María Natalia Gandur Quiroga shared a post on X:

“Exciting news from EORTC! 

• EORTC-1333-GUCG/PEACE III trial has reached its primary endpoint.  
• Compared enzalutamide vs. enzalutamide + radium-223 in asymptomatic or mildly symptomatic castration-resistant prostate cancer patients metastatic to bone.  
• Full results will be presented at an upcoming medical meeting.  

Thanks to the patients, investigators, and research teams for their invaluable participation.  

Date: July 12, Brussels, Belgium.”

Further information.
Source: María Natalia Gandur Quiroga/X

Maria Natalia Gandur Quiroga is a Medical Oncologist and Chief of the Division of Genitourinary Medical Oncology at the Ángel H. Roffo Oncology Institute in Buenos Aires, Argentina. She is a Professor of Medicine at the University of Buenos Aires at the Oncologists Post Graduates Studies. Her research focuses on clinical trials with aims to improve the treatment of patients with urologic tumors.  She is an active member of the European Association for Cancer Research, Argentinian Medical Association and American Society of Clinical Oncology.